Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Facioscapulohumeral muscular dystrophy (FSHD; also called FSH dystrophy, facioscapulohumeral dystrophy or facioscapulohumeral myopathy) is described in the packet definition as an autosomal dominant disorder affecting the skeletal muscles of the face, scapula and upper arm, with muscle weakness that eventually spreads to other skeletal muscles. The packet lists no certified gene entries for this record, so no gene is named in this report. According to expert review (GeneReviews), symptoms typically begin in the teens, although age of onset is variable and some affected individuals remain asymptomatic throughout life. The packet prevalence category is uncommon, with an Orphanet-style estimate of 1 to 9 per 100,000 people; GeneReviews separately cites an estimated prevalence of four to ten per 100,000, with regional figures that vary.
According to GeneReviews, FSHD is characterized by progressive muscle weakness involving the face, shoulder girdle, upper arm, lower leg (peroneal muscles) and, in later stages, the hip girdle. Asymmetry is common. Scapular winging is described as the most common initial finding, with sloping shoulders, straight clavicles and pectoral atrophy. Facial weakness is more pronounced in the lower face; earliest signs are often difficulty whistling or sleeping with the eyes partially open, and extraocular, eyelid and bulbar muscles are spared. Biceps and triceps are selectively involved while forearm muscles are spared ("Popeye arms"). Lower abdominal weakness can produce a protuberant abdomen, exaggerated lumbar lordosis and Beevor sign, and peroneal weakness can result in foot drop. Sensation is preserved. Individuals with severe infantile FSHD have muscle weakness at birth.
The packet's HPO-annotated phenotypes include, at very frequent (80-99%) frequency, skeletal muscle atrophy, elevated creatine kinase, mask-like facies, scapular winging, progressive muscle weakness and hyperlordosis; at frequent (30-79%) frequency they include myopathic EMG abnormalities, camptocormia, frequent falls, scoliosis, restrictive ventilatory defect, abnormal retinal vascular morphology and complete right bundle branch block. GeneReviews also describes chronic pain in 82% of individuals, chronic fatigue, an exudative retinopathy clinically indistinguishable from Coats disease that can result in retinal detachment and vision loss, abnormal audiograms in about 15%, and cardiac conduction abnormalities in 5%-13%, typically mild or asymptomatic.
The packet's certified gene list for this record is empty, so no gene associations are stated here, and the inheritance_patterns field is empty; the packet definition describes FSHD as autosomal dominant. According to GeneReviews, FSHD1 (about 95% of FSHD) is an autosomal dominant disorder caused by a heterozygous pathogenic contraction of the D4Z4 repeat array in the subtelomeric region of chromosome 4q35 on a permissive chromosome 4 haplotype. FSHD2 (about 5%) is attributed to hypomethylation of a shortened D4Z4 array on a permissive haplotype, arising from several documented causes, one of them unknown. The packet lists subtypes FSHD1, FSHD2 and two digenic forms (FSHD3 and FSHD4).
GeneReviews reports that approximately 70%-90% of individuals with FSHD1 have a parent with clinical findings, and approximately 10%-30% have a de novo constitutional or mosaic contraction. Penetrance is described as increased with smaller arrays, with significant variation; in one study it was 83% by age 30 years, 95% in males and 69% in females. Allele size is reported to explain roughly 10% of phenotypic variability, and epigenetic and other unknown environmental or genetic factors are described as likely contributors.
According to GeneReviews, FSHD is suspected with weakness predominantly involving facial, scapular stabilizer and/or foot dorsiflexor muscles without ocular or bulbar weakness, often asymmetric; progression of weakness after pregnancy; or prior diagnosis of an inflammatory myopathy refractory to immunosuppression. Supportive findings include creatine kinase that is normal to elevated (usually not above three to five times the upper limit of normal; above 1,500 IU/L suggests an alternate diagnosis), mild myopathic EMG changes, and nonspecific chronic myopathic changes on muscle biopsy. Muscle biopsy is described as now performed only where FSHD is suspected but not confirmed by molecular genetic testing.
GeneReviews states the diagnosis is established by molecular genetic testing identifying a heterozygous pathogenic D4Z4 contraction on a permissive haplotype (FSHD1) or hypomethylation of a shortened D4Z4 array (FSHD2). Alleles with 8-10 repeat units on a permissive haplotype are described as reduced-penetrance, alleles with 7 or fewer as full-penetrance, and 11 or more as normal. Reported approaches include Southern blot analysis and optical genome mapping. GeneReviews lists limb-girdle muscular dystrophy, mitochondrial myopathies, myofibrillar myopathy, myotonic dystrophy, late-onset Pompe disease and GNE myopathy in the differential diagnosis. The packet contains no newborn screening information.
No FDA-approved treatment for FSHD is certified in this packet. The packet lists orphan drug designation records for FSHD, which are not approvals and do not establish development. Designated entries include an antibody oligonucleotide conjugate (siRNA) from Avidity Biosciences, losmapimod (Fulcrum Therapeutics), nandrolone (Sarcomed AB), an AAV-based gene therapy (Armatus Bio), rebastinib (Genea Biocells US) and a small molecule inhibitor (Altay Therapeutics); a follistatin fusion protein (Acceleron Pharma) and a recombinant histidyl tRNA synthetase (aTyr Pharma) are WITHDRAWN. Three other records list complex regional pain syndrome indications and are not described as FSHD treatments.
According to GeneReviews, standards of care were agreed at the 171st ENMC International Workshop. Documented management includes physical therapy and assistive devices for weakness; ankle-foot orthoses for foot drop; occupational and speech therapy in infantile onset; surgical fixation of the scapula, described as offered cautiously with risk-benefit consideration; pain medication classes (NSAIDs for acute pain, antidepressants or anti-seizure medications for chronic pain); ventilatory support such as BiPAP for hypoventilation as necessary; ocular lubricants for exposure keratitis; treatment per an ophthalmologist for exudative retinopathy; and amplification for hearing loss.
According to GeneReviews, progression is usually slow, although many affected individuals describe a stuttering course with periods of disease inactivity followed by periods of rapid deterioration. Earlier onset is associated with more progression, and eventually 20% of affected individuals require a wheelchair. Some individuals remain asymptomatic throughout their lives. GeneReviews reports a correlation between large D4Z4 contractions and earlier onset, loss of ambulation at a younger age and lower muscle strength, while also noting significant variation and studies that did not confirm the correlation. It describes a study in which neither de novo variants nor earlier onset were associated with a more severe phenotype, in contrast to other studies, and cautions that ascertainment bias may contribute. Life expectancy and survival figures are not certified in this packet.
The packet reports 23 active clinical trial records for FSHD; ten are detailed. These include NCT07038200 (Phase 3, recruiting, Avidity Biosciences; title refers to Del-brax, also called AOC 1020), NCT06547216 (Phase 2 open-label extension of AOC 1020, active not recruiting), NCT07435129 (Phase 2, apitegromab, recruiting, Scholar Rock), NCT06907875 (Phase 1 of EPI-321, active not recruiting, Epicrispr Biotechnologies) and NCT07798609 (Phase 1, SFL-0821, recruiting, Soufflé Therapeutics). Other records include a natural history study of FSHD2 (NCT06079567), a trial readiness study (NCT03458832), an MRI biomarker study (NCT01671865) and the United Kingdom FSHD Patient Registry (NCT04001582). Trial titles alone do not establish the intervention or its effects.
GeneReviews lists therapies under investigation including siRNA-based genetic treatments, an epigenetic 4q35 silencing treatment delivered by adenovirus (EPI-321), losmapimod (improved reachable workspace and strength in both treatment and placebo groups) and a monoclonal antibody to myostatin in Phase II trials. The packet's literature digest classifies 276 publications, with basic science and preclinical work dominant. The packet lists no patient organizations.
Data assembled from 7 of 12 sources · Last updated Nov 17, 2026, 6:42 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
26 trials found
AI-curated news mentioning facioscapulohumeral muscular dystrophy
Updated Nov 17, 2026
d4z4 methylation and genetic modifiers influence severity in a facioscapulohumeral muscular dystrophy kindred
Recent research combines qualitative and quantitative MRI to demonstrate short-term progression in facioscapulohumeral muscular dystrophy. This study enhances understanding of disease progression, which could inform future therapeutic strategies.
A new study demonstrates the use of Oxford Nanopore long-read sequencing for the integrated genetic and epigenetic diagnosis of facioscapulohumeral muscular dystrophy. This approach may enhance diagnostic accuracy for this rare condition.
Epicrispr secures funding to support clinical development of EPI-321, a gene therapy targeting muscular dystrophy treatment Ultimately, our vision is to establish programmable epigenetic medicines as an entirely new therapeutic modality, with the potential to treat diseases that have historically been beyond the reach of conventional approaches.” · Related:Poolbeg CEO delves inside the UK’s record $2.84bn fundraising quarter ... The LSX USA Congress gathers leaders from the US biotech, medtech, and healthtech sectors to network, showcase innovations, and explore partnership opportunities. Related:Vaderis secures $152m to advance rare disease treatment · EPI-321 is designed to be delivered intravenously via a single adeno-associated virus (AAV) vector. The drug aims to durably suppress pathological DUX4 expression without permanently altering the underlying DNA sequence. This Series C marks a shift in the company's fundraising approach compared with earlier rounds, according to Salzman. Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting hundreds of thousands of people worldwide. There are currently no approved disease-modifying therapies. Salzman shared that the disease is a perfect match for the company's approach.
Epicrispr Biotechnologies and Infinimmune have secured a combined $165 million in venture capital funding. Epicrispr aims to develop an epigenetic treatment for facioscapulohumeral muscular dystrophy, while Infinimmune will focus on advancing antibodies for atopic dermatitis.